Previous close | 67.72 |
Open | 66.92 |
Bid | 66.77 x 1000 |
Ask | 66.78 x 1200 |
Day's range | 66.36 - 66.96 |
52-week range | 53.52 - 76.56 |
Volume | |
Avg. volume | 5,238,241 |
Market cap | 206.446B |
Beta (5Y monthly) | 0.17 |
PE ratio (TTM) | 33.64 |
EPS (TTM) | 1.98 |
Earnings date | N/A |
Forward dividend & yield | 1.45 (2.14%) |
Ex-dividend date | 10 Aug 2023 |
1y target est | 83.71 |
AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Fasenra and Farxiga should keep driving revenues. Its pipeline is strong, with several phase III data readouts lined up.
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
In the latest trading session, Astrazeneca (AZN) closed at $67.42, marking a -0.77% move from the previous day.